Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 16/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | XIAP | P98170 | 2/20 | 0.33 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL230923 | 0.93 | ELANE (0.33) | ELANECMA1 | |
| SCHEMBL2289363 | 0.90 | ELANE (0.42) | ELANECMA1XIAPMLX | |
| SCHEMBL5487413 | 0.89 | ELANE (0.38) | ELANECMA1XIAPMLX | |
| SCHEMBL3276266 | 0.87 | ELANE (0.42) | ELANECMA1XIAPMLX | |
| SCHEMBL8662040 | 0.87 | ELANE (0.40) | ELANECMA1XIAPMLX | |
| SCHEMBL535732 | 0.83 | ACE (0.40) | — | |
| SCHEMBL387694 | 0.81 | TACR1 (0.40) | ELANECMA1XIAPMLX | |
| SCHEMBL5494650 | 0.81 | ELANE (0.40) | ELANECMA1XIAPMLX | |
| SCHEMBL8661389 | 0.78 | ELANE (0.36) | ELANECMA1 | |
| SCHEMBL847832 | 0.78 | CMA1 (0.49) | CMA1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964350-B1 | Sample preparation for in situ nucleic acid analysis | APPLIED BIOSYSTEMS, LLC (US) | 2011-06-21 | — | — | US | claimed |
| CN-101434945-A | Nematophagous fungi infectious extracellular serine proteinase crystal morphology | UNIV YUNNAN (CN) | 2009-05-20 | — | — | CN | claimed |
| US-5683867-A | NUCLEIC ACID LIGANDS, BLENDING, PARTITIONING AND AMPLIFICATION | NEXSTAR PHARMACEUTICALS, INC. (US) | 1997-11-04 | — | — | US | claimed |
| US-20240226610-A1 | TOPICAL SKIN FORMULATIONS | MARY KAY INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226216-A1 | METHODS AND COMPOSITIONS FOR TREATING STRIAE DISTENSAE | MARY KAY INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240216262-A1 | COSMETIC COMPOSITIONS AND METHODS OF USING SAME | MARY KAY INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-12005135-B2 | Barrier guard technology | MARY KAY INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240165014-A1 | COSMETIC COMPOSITIONS | MARY KAY INC. | 2024-05-23 | — | — | US | disclosed |
| EP-3851093-B1 | TOPICAL COMPOSITIONS | MARY KAY INC (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240157177-A1 | COSMETIC COMPOSITIONS AND USES THEREOF | ALLUSTRA TECHNOLOGIES LLC | 2024-05-16 | — | — | US | disclosed |
| EP-4363062-A1 | TOPICAL COMPOSITION AGAINST FINE LINES AND WRINKLES | Mary Kay, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20030077646-A1 | Systematic evolution of ligands by exponential enrichment: blended SELEX | GILEAD SCIENCES, INC. (US) | 2003-04-24 | — | — | US | disclosed |
| US-6465189-B1 | PARTITIONING AND REPLICATING INCREASED AFFINITY BLENDED NUCLEIC ACIDS; DEVELOPMENT OF ELASTASE INHIBITORS; MEDICAL DIAGNOSIS OF RESPIRATORY SYSTEM, GENETIC, AND RHEUMATIC DISORDERS | GILEAD SCIENCES, INC. | 2002-10-15 | — | — | US | disclosed |
| US-6465189-B1 | PARTITIONING AND REPLICATING INCREASED AFFINITY BLENDED NUCLEIC ACIDS; DEVELOPMENT OF ELASTASE INHIBITORS; MEDICAL DIAGNOSIS OF RESPIRATORY SYSTEM, GENETIC, AND RHEUMATIC DISORDERS | GILEAD SCIENCES, INC. | 2002-10-15 | — | — | US | disclosed |
| US-6083696-A | DETECTION OF BLENDED NUCLEIC ACID LIGANDS OF A TARGET COMPOUND; INCUBATION OF BLENDED NUCLEIC ACID MIXTURE WITH THE TARGET, SEPARATING BLENDED NUCLEIC ACIDS WITH INCREASED RECEPTIVITY, AMPLIFYING BLENDED NUCLEIC ACIDS | NEXSTAR PHARMACEUTICALS, INC. (US) | 2000-07-04 | — | — | US | disclosed |
| US-5734034-A | Nucleic acid ligand inhibitors of human neutrophil elastase | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-03-31 | — | — | US | disclosed |
| US-5683867-A | NUCLEIC ACID LIGANDS, BLENDING, PARTITIONING AND AMPLIFICATION | NEXSTAR PHARMACEUTICALS, INC. (US) | 1997-11-04 | — | — | US | disclosed |
| EP-0724647-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NeXstar Pharmaceuticals, Inc. (US) | 1996-08-07 | — | — | EP | disclosed |
| US-5472841-A | Partitioning the increased affinity nucleic acids from remainder mixture, amplifying the nucleic acids to yield high affinity nucleic acid | NEXSTAR PHARMACEUTICALS, INC. (US) | 1995-12-05 | — | — | US | disclosed |
| WO-1995007364-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NEXSTAR PHARMACEUTICALS, INC. (US) | 1995-03-16 | — | — | WO | disclosed |